Antigenic preparations and isolation of such preparations

• US 6,210,685 B1
• Filed: 06/17/1999
• Issued: 04/03/2001
• Est. Priority Date: 05/12/1984
• Status: Expired due to Fees

• Current Assignee: Celltech Pharmaceuticals Limited
• Original Assignee: Medeva Pharma Ltd.
• Inventors: Novotny, Pavel, Ivanyi, Juraj, Crespo, Juan Antonio Montaraz
• Primary Examiner(s): Smith, Lynette R. F.
• Assistant Examiner(s): DEVI, SARVAMANGALA J N
• Application Number:
  US09/334,690
• Time in Patent Office: 656 Days
• Field of Search: 424/240.1, 424/254.1, 424/253.1, 424/184.1, 424/234.1, 530/350, 530/825, 530/412, 514/2
• US Class Current: 424/254.1
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: C07K 14/235 from Bordetella (G)
• CPC Class Codes: C12N 9/88 Lyases (4.)
• CPC Class Codes: Y10S 530/806 Antigenic peptides or proteins
• CPC Class Codes: Y10S 530/825 Bacteria

Abstract

The present invention provides novel antigenic preparations comprising proteinaceous material associated with adenylate cyclase activity in cultures of B. pertussis, the said preparations being useful as components of acellular whooping cough vaccines. The invention further provides methods for the isolation of such antigenic preparations.

Claims

1. Bordetella pertussis antigen useful for making a vaccine,

wherein the antigen is characterized by (a) having a relative molecular weight of about 67,000 to 73,000 Daltons as determined by 12% (w/w) polyacrylamide gel electrophoresis and (b) binding to the monoclonal immunoglobulin secreted by the hybridoma deposited at the European Collection of Animal Cell Cultures, Porton Down, United Kingdom, under accession number 90010501, and

wherein the antigen is in an amount effective to induce an immune reaction to said antigen in a patient.

2. The antigen of claim 1, wherein the antigen has a relative molecular weight of about 69,000 Daltons as determined by 12% (w/w) polyacrylamide gel electrophoresis.

3. The antigen of claim 1, wherein said antigen is substantially free of lipopolysaccharides.

4. The antigen of claim 1, wherein the antigen is purified.

5. The antigen of claim 2, wherein the antigen is purified.

6. The antigen of claim 2, wherein said antigen is substantially free of lipopolysaccharides.